Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans aim to uncover early signs of psychosis

NCT ID NCT06977308

Knowledge-focused Sponsor: New York State Psychiatric Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study uses brain scans to examine dopamine, a key brain chemical, in 115 people aged 18-30 who are at high risk for psychosis. Participants will have PET and MRI scans and be followed for up to two years to see if they develop psychosis. The goal is to understand where and when dopamine becomes abnormal, which could help develop better treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 115 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females between 18 and 30 years old 2. Capacity to give informed consent 3. Clinical High Risk (i.e., APSS, GRDS, BIPS) 4. Antipsychotic free for 3 weeks before the PET scan 5. Clinically stable enough for the study Exclusion Criteria: 1. Any substance use disorder, of any severity, within the previous month (before PET scan; not including nicotine or caffeine) 2. Any current use of substance of abuse besides THC/marijuana/cannabis/nicotine/caffeine (on day of PET only) 3. Daily tobacco use 4. Pregnancy 5. Lactation 6. Presence of insulin-dependent diabetes 7. IQ \< 70 (i.e., WTAR \< 6) 8. Acute risk for suicide (i.e., score of 4-5 within the previous month or 6 within the previous 3 months on the CSSRS) or violence, or history of severe violent behavior that may be exacerbated by methylphenidate 9. Presence of metallic objects in the body 10. Lifetime exposure to radiation in the workplace (i.e., being badged for radiation exposure), or exposure to radiation in the context of research protocol within the previous year that exceeds annual limits 11. More than one risk factor for coronary artery disease (e.g., smoking, hyperlipidemia, sedentary lifestyle) 12. Hypertension 13. Presence of clinically significant brain abnormalities. \[For PET Scan Only\] 14. Previous adverse reaction to stimulants that would preclude receiving methylphenidate 15. Presence or positive history of any cardiovascular disease, medical or neurological condition that would preclude methylphenidate administration or participation in this study 16. A history of bipolar disorder Type 1, or any history of syndromal psychosis 17. Lack of effective birth control

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical high risk for psychosis (CHR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical high risk for psychosis (CHR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.